| Prev Close | 55.00 |
| Open | 54.59 |
| Day Low/High | 53.76 / 55.27 |
| 52 Wk Low/High | 36.15 / 57.44 |
| Volume | 4.46M |
| Avg Volume | 5.23M |
AstraZeneca Plc (AZN)
53.87
1.10
2.10
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.62B |
| Market Cap | 140.76B |
| EPS | 0.50 |
| P/E Ratio | 24.54 |
| Div & Yield | 1.37 (2.48%) |
Lunacy on Interest Rates
Across all sectors, stocks are rising in tandem with rates -- but I think this stupidity will end soon.
AstraZeneca Zigs and Zags
The shares have more moves than a shortstop batting .110. From bottom to high to bottom to high, AstraZeneca (AZN) has traversed about 9 points today. More moves than a shortstop batting .110.
The Early Bird Gets the Worm, Part Deux
I sold out of my AstraZenca long for a nice gain. I just sold out of the balance of my AstraZeneca (AZN) long rental at $72.30, a nice way to start the day.
The Early Bird Gets the Worm
Just collected some profits on my premarket AstraZeneca purchase. I just sold out more than half of my AstraZeneca (AZN) long rental at $71.90, for more than a $1.20-per-share gain.
Morning Market Look
Maybe the rally has simply been too soon and too fast. There was little in the way of weekend news that would lead one to expect a down futures opening. So, maybe the rally has simply been too soon and too fast. There was some dovish news on Bernank...
Pfizer, AstraZeneca CEOs Set to Appear Before UK Lawmakers
In an effort to smooth approval for its $106 billion merger, Pfizer and AstraZeneca are set to meet UK regulators on Tuesday who are wary a deal will lead to British job cuts.
Worry About Bonds, Not Bubbles
The biggest overvaluation is the undervaluation of risk in that market.
An Economy Stuck in First Gear
These two structural issues go a long way toward explaining this sluggish growth.
AstraZeneca Spurns Pfizer Bid, Earnings News & a Jim Cramer Pick
LinkedIn is among loss leaders on the tech scene in 2014, and its earnings report Thursday did little to improve investors' outlook.
Pfizer's Blockbuster Bid, Yahoo's Laugh Track & Americans Take Off
Pharma giant Pfizer revealed Monday it made a $99 billion bid for AstraZeneca in January and had contacted its rival again on April 26 about a takeover.
The Revenge of the Nerds
Suddenly these companies have gone from embarrassing to, yes, embarrassingly rich.
Covered AstraZeneca Short
That was quick. I have covered my AstraZeneca (AZN) short for a quick profit.
Adding to AZN Short
I am adding to my AstraZeneca (AZN) short at $67.35 now.
Day Ahead: Earnings in Full Swing
Futures point higher; AstraZeneca rises on bid talk.
Shorting AZN
I doubt this story. A London Sunday Times article suggests that Pfizer (PFE) considered acquiring AstraZeneca (AZN), but the talks stalled and will not resume. I am doubtful of this story and I have shorted AZN, +$6 in premarket trading as the compa...
Array CEO: Partnerships Smart While Cancer Drug Develops
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart
James Molloy, Managing Director at Janney Montgomery Scott explains why Actavis buying Forest Labs is a smart for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
European Stocks Rally on Fed Guidance; Drugmakers Strike Deals
The U.K.'s AstraZeneca and Germany's Bayer spend up to a combined $7.2 billion shoring up their portfolios. Laura Board reports from London.
Keep Calm and Carry EWU
The UK is the next geographic hotspot. Play it with this ETF.
S&P Lifts U.S. Credit Outlook
Credit rating agency Standard & Poor's upgrades its credit outlook for the U.S. government to Stable from Negative.
Stocks Follow Japan's Lead Upward
Merger Monday begins with AstraZeneca buying Pearl, while Apple could announce iRadio and Google may purchase Waze as futures look up.
Millions for Fish Oil
Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.
The Biotech Revaluation Is On
These four names in particular have made some stunning moves.
Trending Now: HPQ Announces 10% Increase in Quarterly Dividend
Hewlett-Packard announces a 10% increase in its quarterly dividend. Brittany Umar has details on that as well as a look at the day's other most searched trends on the Web.
IPOs: LifeLock, Luxfer, Regulus
LifeLock looks to be the best offering for the IPOs planned on Wednesday according to IPO Desltop President Francis Gaskins.
Three U.K. Gold Medalists
These companies are performing like champions, despite a weak British economy.
Trading Abbott for Bristol Myers
Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.
Apple Pays Proview $60 Million in iPad Dispute: Hot Trends
A look at some of the day's most searched topics on the Web, includingApple as the company shells out $60 million to settle its iPad namingdispute with Proview Technology.
The Next Big Thing in Biotech: M&A
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
